09.05.2024  17:13:18 Diff. +0,70 Volumen Geld17:13:18 Brief17:13:20 Marktkapitalisierung Dividendenr. KGV
328,50GBX +0,21% 1,26 Mio.
Umsatz(GBP): 4,13 Mio.
328,40Geld Vol: 1.566 328,60Brief Vol: 1.049 30,4 Mrd.GBP - -

Unternehmensportrait

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. It provides oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands includes Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum.
 

Vorstand & Aufsichtsrat

Vorstandsvorsitzender
Brian McNamara
Vorstand
Tobias Hestler, Keith Choy, Filippo Lanzi, Mairéad Nayager, Lisa Paley, Franck Riot, Tamara Rogers, Bjarne Philip Tellmann, Ed Petter, Björn Timelin, Namrata Patel
Aufsichtsrat
Sir Dave Lewis , Brian McNamara , Tobias Hestler, Mavinder Singh (Vindi) Banga , Marie-Anne Aymerich , Tracy Clarke, Dame Vivienne Cox, Asmita Dubey, Deirdre Mahlan, Bryan Supran, David (Dave) Denton
 

Unternehmensinformationen

Name: Haleon PLC ORD GBP0.01
Adresse: The Heights Building 5, First Floor The Heights,Surrey KT13 0NY
Telefon: -
Fax: -
E-Mail: -
Internet: https://www.haleon.com/
Industrie: Gesundheitswesen
Sektor: Pharmazeutische Industrie
Sub-Sektor: Pharmazeutische Industrie
Ende des Finanzjahres: 31.12
Streubesitz: -
IPO Datum: -

Investor Relations

Name: -
IR Telefon: -
IR Fax: -
IR E-Mail: investor-relations@haleon.com

Unternehmenskalender

KW 20 | 16.05.2024 Dividendenzahlung
 

Hauptaktionäre

Sonstige
 
55,00%
Pfizer
 
32,00%
GSK
 
13,00%